On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the companyﾒs COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, that may help treat or prevent infection with SARS-CoV-2, the coronavirus that causes COVID-19.